Compare EQR & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EQR | WST |
|---|---|---|
| Founded | 1993 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5B | 20.2B |
| IPO Year | 1993 | N/A |
| Metric | EQR | WST |
|---|---|---|
| Price | $61.90 | $260.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 7 |
| Target Price | $69.92 | ★ $338.00 |
| AVG Volume (30 Days) | ★ 2.3M | 706.4K |
| Earning Date | 02-05-2026 | 02-12-2026 |
| Dividend Yield | ★ 4.46% | 0.34% |
| EPS Growth | ★ 24.49 | 0.17 |
| EPS | 3.03 | ★ 6.75 |
| Revenue | ★ $3,078,827,000.00 | $3,017,900,000.00 |
| Revenue This Year | $5.10 | $6.97 |
| Revenue Next Year | $3.38 | $6.27 |
| P/E Ratio | ★ $20.45 | $38.48 |
| Revenue Growth | 4.69 | ★ 4.92 |
| 52 Week Low | $58.38 | $187.43 |
| 52 Week High | $75.86 | $348.90 |
| Indicator | EQR | WST |
|---|---|---|
| Relative Strength Index (RSI) | 51.92 | 37.75 |
| Support Level | $59.10 | $267.82 |
| Resistance Level | $63.39 | $281.55 |
| Average True Range (ATR) | 1.26 | 8.88 |
| MACD | -0.13 | -1.13 |
| Stochastic Oscillator | 54.02 | 1.84 |
Equity Residential owns a portfolio of 312 apartment communities with over 84,000 units and is developing two additional properties with 655 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.